STOP! Are these Two Hidden Flaws Tanking Promising Biotech Trials? The FDA is watching!

Sharp analysis reveals the critical design missteps that can stall groundbreaking medical research. When an oncology trial sees more than half its candidates fail initial screening, it strongly suggests eligibility criteria are unnecessarily restrictive, directly causing painful enrollment delays. Adding to the complexity, the current regulatory environment raises serious concerns for studies attempting to advance into Phase III without a robust control arm. Relying on 'physician's choice' as a benchmark, for instance, often introduces too much variability, ultimately yielding noisy and unreliable data for decision-makers.
#Biotech #ClinicalTrials #DrugDevelopment #OncologyResearch #FDA #TrialDesign #MedicalScience #BiotechInvesting

Видео STOP! Are these Two Hidden Flaws Tanking Promising Biotech Trials? The FDA is watching! канала Dan Sfera